Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Posted: January 6, 2024 at 2:37 am

– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 –

See original here:
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Related Posts